NuVasive To Expands Global Presence, Pediatric Portfolio With Ellipse Buy
This article was originally published in Clinica
On Jan. 5, NuVasive said it agreed to buy Ellipse in a deal that is expected to be complete by the end of February. NuVasive will pay an additional $30 million in 2017 if Ellipse's portfolio meets certain revenue targets.
You may also be interested in...
Earnings Winners And Losers: BSX, BCR, NUVA, NVCR
Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.
Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.